profit from every $100 of sales.
$0$100
Tango Therapeutics
$25.73+5.88% today
+207.0% in 1 year
1-year low $7.671-year high $32.90
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Tango Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $24.9 million in 2022 to $62.4 million in 2025, with -$102 million of profit last year.
SalesProfit
Tango Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Tango Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Tango Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 8 | 37 | 25 | 37 | 42 | 62 | |
| – | – | – | – | – | – | |
| -52 | -58 | -111 | -114 | -146 | -111 | |
| -51 | -57 | -109 | -112 | -143 | -109 | |
| -52 | -58 | -108 | -102 | -130 | -102 | |
| -1.63 | -0.94 | -1.23 | -1.08 | -1.19 | -0.87 | |
| – | – | – | – | – | – | |
| -681.8% | -157.1% | -446.8% | -312.6% | -346.1% | -178.4% | |
| -678.8% | -157.2% | -435.1% | -278.5% | -309.7% | -162.9% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 207 | 500 | 436 | 403 | 316 | 399 |
| Cash | 28 | 143 | 60 | 66 | 70 | 112 |
| Total debt | – | – | 41 | 39 | 36 | 34 |
| Total liabilities | 169 | 155 | 187 | 149 | 117 | 53 |
| 39 | 345 | 249 | 253 | 200 | 346 | |
| – | 62 | 88 | 95 | 109 | 116 | |
| -106.8% | -13.3% | -30.2% | -30.9% | -48.7% | -23.2% | |
| -134.6% | -16.9% | -43.4% | -40.2% | -65.3% | -29.3% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 70 | -60 | -109 | -118 | -132 | -139 | |
| 1 | 2 | 8 | 2 | 1 | 1 | |
| 69 | -61 | -117 | -120 | -132 | -140 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 2 | 8 | 14 | 19 | 29 | 26 |
Valuation
- –
- –
- –
- 10.5×
- 69.9×
- –
- –
- -3.2%
- -2.3%
- 0.0%
Profitability
- 97.3%
- -178.4%
- -162.9%
- -168.4%
- -23.7%
- -34.1%
- -50.3%
- -25.5%
- -29.5%
- 211.9%
Growth
- +52.1%
- –
- −5.8%
- –
- +9.8%
Financial health
- -0.7×
- 0.10
- 8.4%
- –
- 16.32
- 16.32
- 0.16
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 17%of 958
Bottom 1%of 889
Top 12%of 890
Bottom 22%of 987
What analysts expect
- Average price target
- $22.75
- Range
- $14.00 – $40.00
- 4 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.32 | -0.32 | +0.0% |
| Mar 5, 2026 | -0.29 | -0.31 | +6.5% |
| Nov 4, 2025 | 0.13 | 0.01 | +1,200.0% |
| Aug 5, 2025 | -0.35 | -0.35 | +0.0% |
| May 12, 2025 | -0.36 | -0.34 | −5.9% |
| Feb 27, 2025 | -0.35 | -0.32 | −9.4% |
| Nov 6, 2024 | -0.27 | -0.34 | +20.6% |
| Aug 7, 2024 | -0.24 | -0.34 | +29.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
41No pass
Philip Fisher
53No pass
Peter Lynch
73Pass
Joel Greenblatt
2No pass
Charlie Munger
41No pass
Terry Smith
51No pass
Questions about Tango Therapeutics
Is Tango Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Tango Therapeutics AI analysis
What does Tango Therapeutics do?
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. It is in Biotechnology, based in Boston, MA, United States, with 137 employees.
Does Tango Therapeutics pay a dividend?
No. Tango Therapeutics does not pay a dividend at the moment.
Is Tango Therapeutics stock halal?
Yes. Tango Therapeutics passes our halal screen: its business is permitted and its debt is 0.8% of its market value, under the 30% limit. How we check
How has Tango Therapeutics stock done over the past year?
Up 207.0% over the past twelve months, to $25.73. It traded between $7.67 and $32.90 and is 21.8% below its high.
Who are Tango Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Tango Therapeutics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.